125010-32-4

Basic information

• Product Name: 2-METHYLENE-PENTANEDIOIC ACID DI-TERT-BUTYL ESTER
• Synonyms: 2-METHYLENE-PENTANEDIOIC ACID DI-TERT-BUTYL ESTER
• CAS NO: 125010-32-4
• Molecular Formula: C₁₄H₂₄O₄
• Molecular Weight: 256.33796
• Mol File: 125010-32-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-METHYLENE-PENTANEDIOIC ACID DI-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYLENE-PENTANEDIOIC ACID DI-TERT-BUTYL ESTER(125010-32-4)
• EPA Substance Registry System: 2-METHYLENE-PENTANEDIOIC ACID DI-TERT-BUTYL ESTER(125010-32-4)

Safety Data

• Hazardous Substances Data: 125010-32-4(Hazardous Substances Data)

Upstream product

• 125028-97-9 di-t-butyl 2-hydroxymethyl-3-methylenesuccinate 
• 1663-39-4 tert-Butyl acrylate 

Downstream Products

• 229472-51-9 4,4'-phosphinicobis(butane-1,3-dicarboxylic acid) 
• 947171-27-9 C₃₃H₄₇N₆O₈P 
• 947171-13-3 2-[((4-amino-phenyl)(methoxy)-phosphinoyl)-methyl]pentane-1,5-dioic acid di-tert-butyl ester 
• 947171-08-6 2-[((4-(N-benzyloxycarbonyl-amino)-phenyl)(methoxy)-phosphinoyl)-methyl]pentane-1,5-dioic acid di-tert-butyl ester 
• 875668-30-7 2-[(3-benzyloxycarbonylamino-3-tert-butoxycarbonyl-propyl)-hydroxy-phosphinoylmethyl]-pentanedioic acid di-tert-butyl ester 

Relevant articles and documents

A short large scale synthesis of (±) sarkomycin esters

-

Prodrug forms of N-[(4-deoxy-4-amino-10-methyl)pteroyl]glutamate-γ- [ψP(O)(OH)]-glutarate, a potent inhibitor of folylpoly-γ-glutamate synthetase: Synthesis and hydrolytic stability

Ester prodrugs of the phosphinate pseudopeptide N-[(4-deoxy-4-amino-10- methyl)pteroyl]glutamate-γ-[ψP-(O)(OH)]-glutarate (1a) were synthesized. H-phosphinic acids derived from N-Cbz vinyl glycine esters were converted to the desired pseudopeptides by Michael addition to α-methyleneglutarate esters. Pivaloyloxymethyl (POM) ester moieties were incorporated in both the N-terminal and C-terminal fragments prior to formation of either C-P bond, N-Alkylation of the corresponding amides derived from N-(N-methyl)aminobenzoic acid with 2,4-diamino-6-(bromomethyl)pteridine gave the target compounds. POM esters of methotrexate and the corresponding γ-glutamyl conjugate were also synthesized using the same strategy. All prodrugs were evaluated in Chinese hamster ovary cells. Although the pseudopeptide prodrugs were ineffective, prodrugs of methotrexate and the corresponding γ-glutamyl conjugate were equipotent with the parent compounds. Stability of the prodrugs was investigated in both phosphate buffer and cell line medium to provide a rationale for the observed biological data.

Design and pharmacological activity of phosphinic acid based NAALADase inhibitors

A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive model of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

Phosphinic alkanoic acid derivatives

The present invention relate to phosphinic alkanoic acid derivatives that inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising the same, and methods of using the same to inhibit NAALADas